Tubulis Presents Preclinical Data for Solid Tumor Targeting ADC Candidates TUB-030 and TUB-040 Demonstrating Superior Efficacy Profile and a Wide Therapeutic Window at the AACR Annual Meeting 2024

Tubulis today presented comprehensive preclinical data on its two lead antibody-drug conjugate (ADC) candidates TUB-030 and TUB-040 at this year's Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. The poster...

Related Keywords

San Diego ,California ,United States ,American ,Tubuli Tubutecan ,Jonas Helma Smets ,Tubutecan Adcs ,Linkedin ,Product Service ,Presents Preclinical Data ,Solid Tumor Targeting ,Superior Efficacy Profile ,Wide Therapeutic Window ,Annual Meeting ,American Association ,Cancer Research ,Chief Scientific Officer ,Fc Silenced Igg ,